FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Waldemar Debinski

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Amanda Beauchamp; Denise M Gibo; Mark O Lively; Akiva Mintz; Jill Wykosky; Waldemar Debinski
EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.
Hetal Pandya; Waldemar Debinski
Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.
Amanda Beauchamp; Waldemar Debinski
Ephs and ephrins in cancer: ephrin-A1 signalling.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Waldemar Debinski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Amanda Beauchamp; Denise M Gibo; Mark O Lively; Akiva Mintz; Jill Wykosky; Waldemar Debinski
EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.
Molecular and cellular biology 2012;32(16):3253-64.
2012: Hetal Pandya; Waldemar Debinski
Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2012;26(4):235-44.
2012: Amanda Beauchamp; Waldemar Debinski
Ephs and ephrins in cancer: ephrin-A1 signalling.
Seminars in cell & developmental biology 2012;23(1):109-15.
2011: Waldemar Debinski; Denise M Gibo
Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells.
Cancer biology & therapy 2011;11(2):254-62.
2010: Waldemar Debinski; Stephen B Tatter
Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation.
Current opinion in molecular therapeutics 2010;12(6):647-53.
2010: Hetal Pandya; Denise M Gibo; Waldemar Debinski
Molecular targeting of intracellular compartments specifically in cancer cells.
Genes & cancer 2010;1(5):421-33.
2009: Waldemar Debinski; Stephen B Tatter
Convection-enhanced delivery for the treatment of brain tumors.
Expert review of neurotherapeutics 2009;9(10):1519-27.
2009: M L Tanaka; Waldemar Debinski; I K Puri
Hybrid mathematical model of glioma progression.
Cell proliferation 2009;42(5):637-46.
2009: Tie Fu Liu; Jiaozhong Cai; Denise M Gibo; Waldemar Debinski
Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):160-8.
2008: Jill Wykosky; Waldemar Debinski
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Molecular cancer research : MCR 2008;6(12):1795-806.
2008: Akiva Mintz; Denise M Gibo; A B Madhankumar; Nancy M Cladel; Neil D Christensen; Waldemar Debinski
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.
Cancer biotherapy & radiopharmaceuticals 2008;23(5):581-9.
2008: Waldemar Debinski
Drug cocktails for effective treatment of glioblastoma multiforme.
Expert review of neurotherapeutics 2008;8(4):515-7.
2008: Jill Wykosky; Denise M Gibo; Constance Stanton; Waldemar Debinski
Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):199-208.
2007: Jill Wykosky; Denise M Gibo; Waldemar Debinski
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
Molecular cancer therapeutics 2007;6(12 Pt 1):3208-18.
2007: Judith A Schwartzbaum; Anders Ahlbom; Stefan Lönn; Beatrice Malmer; Annette Wigertz; Anssi Auvinen; Anthony J Brookes; Helle Collatz Christensen; Roger Henriksson; Christoffer Johansen; Tiina Salminen; Minouk J Schoemaker; Anthony J Swerdlow; Waldemar Debinski; Maria Feychting
An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(11):2448-54.
2006: Waldemar Debinski
Naturally occurring, unmodified bacterial toxin for the treatment of glioblastoma multiforme?
Cancer biology & therapy 2006;5(11):1569-70.
2005: Jill Wykosky; Denise M Gibo; Constance Stanton; Waldemar Debinski
EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Molecular cancer research : MCR 2005;3(10):541-51.
2005: Waldemar Debinski
Personalized, multivalent, and more affordable: the globalization of vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5663-4.
2005: Judith A Schwartzbaum; Anders Ahlbom; Beatrice Malmer; Stefan Lönn; Anthony J Brookes; Hani Doss; Waldemar Debinski; Roger Henriksson; Maria Feychting
Polymorphisms associated with asthma are inversely related to glioblastoma multiforme.
Cancer research 2005;65(14):6459-65.
2005: Waldemar Debinski; Denise M Gibo
Fos-related antigen 1 modulates malignant features of glioma cells.
Molecular cancer research : MCR 2005;3(4):237-49.
2004: AB Madhankumar; Akiva Mintz; Waldemar Debinski
Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.
Neoplasia (New York, N.Y.) 2004;6(1):15-22.
2003: Akiva Mintz; Denise M Gibo; AB Madhankumar; Waldemar Debinski
Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
Journal of neuro-oncology 2003;64(1-2):117-23.
2003: Waldemar Debinski; Denise M Gibo; Akiva Mintz
Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors.
Annals of the New York Academy of Sciences 2003;983():232-42.
2002: Guoying Zhou; Guo-Jie Ye; Waldemar Debinski; Bernard Roizman
Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(23):15124-9.
2002: AB Madhankumar; Akiva Mintz; Waldemar Debinski
Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine.
The Journal of biological chemistry 2002;277(45):43194-205.
2002: Akiva Mintz; Denise M Gibo; Becky Slagle-Webb; Neil Christensen; Waldemar Debinski
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.
Neoplasia (New York, N.Y.) 2002;4(5):388-99.
2002: Waldemar Debinski
Local treatment of brain tumors with targeted chimera cytotoxic proteins.
Cancer investigation 2002;20(5-6):801-9.
2001: Waldemar Debinski; Becky Slagle-Webb; Marc G Achen; Steven A Stacker; E Tulchinsky; GY Gillespie; Denise M Gibo
VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme.
Molecular medicine (Cambridge, Mass.) 2001;7(9):598-608.
2001: K T Nash; JP Thompson; Waldemar Debinski
Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins.
Critical reviews in oncology/hematology 2001;39(1-2):87-98.
2000: Waldemar Debinski; B Slagle; Denise M Gibo; S K Powers; GY Gillespie
Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
Journal of neuro-oncology 2000;48(2):103-11.
2000: Waldemar Debinski; Denise M Gibo
Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen.
Molecular medicine (Cambridge, Mass.) 2000;6(5):440-9.
2000: Akiva Mintz; Waldemar Debinski
Cancer genetics/epigenetics and the X chromosome: possible new links for malignant glioma pathogenesis and immune-based therapies.
Critical reviews in oncogenesis 2000;11(1):77-95.
1999: JP Thompson; Waldemar Debinski
Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors.
The Journal of biological chemistry 1999;274(42):29944-50.
1999: Waldemar Debinski; JP Thompson
Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3143s-3147s.
1999: Waldemar Debinski; Denise M Gibo; B Slagle; S K Powers; GY Gillespie
Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme.
International journal of oncology 1999;15(3):481-6.
1999: Waldemar Debinski; Denise M Gibo; SW Hulet; James Connor; GY Gillespie
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(5):985-90.
1999: SW Hulet; Ellen J Hess; Waldemar Debinski; paolo arosio; K Bruce; S Powers; James Connor
Characterization and distribution of ferritin binding sites in the adult mouse brain.
Journal of neurochemistry 1999;72(2):868-74.
1999: Waldemar Debinski
Recombinant cytotoxins specific for cancer cells.
Annals of the New York Academy of Sciences 1999;886():297-9.
1998: Waldemar Debinski; Denise M Gibo; Raj K Puri
Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13.
International journal of cancer. Journal international du cancer 1998;76(4):547-51.
1998: Waldemar Debinski; Denise M Gibo; NI Obiri; A Kealiher; Raj K Puri
Novel anti-brain tumor cytotoxins specific for cancer cells.
Nature biotechnology 1998;16(5):449-53.
1998: Waldemar Debinski
An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link.
Critical reviews in oncogenesis 1998;9(3-4):255-68.
1997: T Murata; NI Obiri; Waldemar Debinski; Raj K Puri
Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells.
Biochemical and biophysical research communications 1997;238(1):90-4.
1997: Atul Maini; Gilda G Hillman; Gabriel P Haas; Ching Y Wang; EJ Montecillo; Fasahat H Hamzavi; J Edson Pontes; Pamela Leland; Ira Pastan; Waldemar Debinski; Raj K Puri
Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin.
The Journal of urology 1997;158(3 Pt 1):948-53.
1997: NI Obiri; T Murata; Waldemar Debinski; Raj K Puri
Modulation of interleukin (IL)-13 binding and signaling by the gammac chain of the IL-2 receptor.
The Journal of biological chemistry 1997;272(32):20251-8.
1997: D J Olson; Denise M Gibo; Gregory C Saggers; Waldemar Debinski; R Kumar
Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1997;8(4):417-23.
1997: Syed R Husain; NI Obiri; P Gill; T Zheng; Ira Pastan; Waldemar Debinski; Raj K Puri
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(2):151-6.
1997: NI Obiri; Pamela Leland; T Murata; Waldemar Debinski; Raj K Puri
The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(2):756-64.
1996: NI Obiri; Syed R Husain; Waldemar Debinski; Raj K Puri
Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1743-9.
1996: Waldemar Debinski; R Miner; Pamela Leland; NI Obiri; Raj K Puri
Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.
The Journal of biological chemistry 1996;271(37):22428-33.
1996: Raj K Puri; Pamela Leland; NI Obiri; Syed R Husain; Robert J Kreitman; Gabriel P Haas; Ira Pastan; Waldemar Debinski
Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Blood 1996;87(10):4333-9.
1995: Waldemar Debinski; NI Obiri; S K Powers; Ira Pastan; Raj K Puri
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(11):1253-8.
1995: Waldemar Debinski; NI Obiri; Ira Pastan; Raj K Puri
A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
The Journal of biological chemistry 1995;270(28):16775-80.
1995: NI Obiri; Waldemar Debinski; Warren J Leonard; Raj K Puri
Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15.
The Journal of biological chemistry 1995;270(15):8797-804.
1994: Raj K Puri; Waldemar Debinski; NI Obiri; Robert J Kreitman; Ira Pastan
Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
Cellular immunology 1994;154(1):369-79.